Literature DB >> 24062873

Impact of botulinum toxin a on the quality of life of subjects following treatment of facial lines.

Ravi Jandhyala1.   

Abstract

OBJECTIVE: To investigate quality of life and its correlation to patient satisfaction before and after treatment with botulinum toxin A.
METHODS: Quality of life was assessed using the Schedule for the Evaluation of Individual Quality of Life Direct-Weighting tool. Patients identified the five areas of their life of the greatest importance to them, weighted the areas as to their relative importance, and rated their status in each area on a visual scale before treatment (old cues) and 28 days later (using both old cues and newly defined and weighted cues). At both visits, patients also rated their overall quality of life using a visual analogue scale. Patient satisfaction with their appearance was measured using a 10-point scale in conjunction with standardized photographs taken at each visit.
RESULTS: Fifty-three patients (median age 39.5 years; 87% women) with moderate-to-severe wrinkles of the glabella, forehead, or crow's feet were enrolled. Treatment with incobotulinumtoxinA consistently resulted in a significant improvement in quality of life according to Schedule for the Evaluation of Individual Quality of Life Direct-Weighting tool index scores (old cues, P=0.0006; new cues P=0.0235) and patient assessment of their overall quality of life (P<0.0001 for both old and new cues). Family, work, finance, relationships, and health were the five most frequently identified cues at each assessment. No correlation between quality of life and satisfaction scores was found, although both were significantly increased after treatment.
CONCLUSION: These results support the contention that quality of life is significantly improved following botulinum toxin A treatment and that consideration should be given to incorporating the measurement of quality of life as an outcome measure following botulinum toxin A treatment, especially as satisfaction does not correlate to quality of life.

Entities:  

Year:  2013        PMID: 24062873      PMCID: PMC3780803     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  15 in total

1.  A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem.

Authors:  Steven H Dayan; John P Arkins; Amit B Patel; Thomas J Gal
Journal:  Dermatol Surg       Date:  2010-11-11       Impact factor: 3.398

2.  OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.

Authors:  R B Lipton; S F Varon; B Grosberg; P J McAllister; F Freitag; S K Aurora; D W Dodick; S D Silberstein; H C Diener; R E DeGryse; M E Nolan; C C Turkel
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

3.  A validated grading scale for crow's feet.

Authors:  Alastair Carruthers; Jean Carruthers; Bhushan Hardas; Mandeep Kaur; Roman Goertelmeyer; Derek Jones; Berthold Rzany; Joel Cohen; Martina Kerscher; Timothy Corcoran Flynn; Corey Maas; Gerhard Sattler; Alexander Gebauer; Rainer Pooth; Kathleen McClure; Ulli Simone-Korbel; Larry Buchner
Journal:  Dermatol Surg       Date:  2008-11       Impact factor: 3.398

4.  A validated grading scale for forehead lines.

Authors:  Alastair Carruthers; Jean Carruthers; Bhushan Hardas; Mandeep Kaur; Roman Goertelmeyer; Derek Jones; Berthold Rzany; Joel Cohen; Martina Kerscher; Timothy Corcoran Flynn; Corey Maas; Gerhard Sattler; Alexander Gebauer; Rainer Pooth; Kathleen McClure; Ulli Simone-Korbel; Larry Buchner
Journal:  Dermatol Surg       Date:  2008-11       Impact factor: 3.398

5.  A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.

Authors:  Matthias Imhof; Ulrich Kühne
Journal:  J Clin Aesthet Dermatol       Date:  2011-10

6.  Facing depression with botulinum toxin: a randomized controlled trial.

Authors:  M Axel Wollmer; Claas de Boer; Nadeem Kalak; Johannes Beck; Thomas Götz; Tina Schmidt; Muris Hodzic; Ursula Bayer; Thilo Kollmann; Katja Kollewe; Daniela Sönmez; Katja Duntsch; Martin D Haug; Manfred Schedlowski; Martin Hatzinger; Dirk Dressler; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  J Psychiatr Res       Date:  2012-02-24       Impact factor: 4.791

Review 7.  A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures.

Authors:  Steven Fagien; Jean D A Carruthers
Journal:  Plast Reconstr Surg       Date:  2008-12       Impact factor: 4.730

Review 8.  Treating glabellar lines with botulinum toxin type A-hemagglutinin complex: a review of the science, the clinical data, and patient satisfaction.

Authors:  Koenraad De Boulle; Steven Fagien; Boris Sommer; Richard Glogau
Journal:  Clin Interv Aging       Date:  2010-04-26       Impact factor: 4.458

9.  Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study.

Authors:  Mitchell A Stotland; Jonathan W Kowalski; Belinda B Ray
Journal:  Plast Reconstr Surg       Date:  2007-10       Impact factor: 4.730

10.  Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines.

Authors:  Boris Sommer; Ina Zschocke; Dorothee Bergfeld; Gerhard Sattler; Matthias Augustin
Journal:  Dermatol Surg       Date:  2003-05       Impact factor: 3.398

View more
  2 in total

Review 1.  Botulinum Toxin Application in Facial Esthetics and Recent Treatment Indications (2013-2018).

Authors:  Vivekanand Kattimani; Rahul Vinay Chandra Tiwari; Khalid Gufran; Bharti Wasan; P H Shilpa; Anas Abdul Khader
Journal:  J Int Soc Prev Community Dent       Date:  2019-04-12

2.  A Multicenter Study to Evaluate Subject Satisfaction With Two Treatments of AbobotulinumtoxinA a Year in the Glabellar Lines.

Authors:  Joel Schlessinger; Joel L Cohen; Ava Shamban; Carolyn Jacob; Kian Karimi; Corey Maas; Vanessa Lane; Sarah Coquis-Knezek; Matthew Meckfessel
Journal:  Dermatol Surg       Date:  2021-04-01       Impact factor: 2.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.